Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202502053 A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (UMBRIEL) New Drug Phase Ⅱ
N202503006 Evaluation of the effectiveness and accuracy of mask rapid screening based on aptamers of MPT64, H37Ra and ManLAM antigens for the detection of Mycobacterium tuberculosis New Medical Device NA
N202503021 A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function after Kidney Transplantation New Drug Phase Ⅲ
N202503077 A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T cell (gdT) Therapy in Adult Subjects with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) New Drug Phase Ⅰ
N202503085 A pilot study to evaluate diagnostic yield rate of InheriNext in children with developmental delay/intellectual disability (DD/ID) by prioritization of pathogenic variants using both whole-exome sequencing and phenotyping data New Medical Device NA
N202503086 A randomized, Phase 2, double-blind, placebo-controlled, parallel-group, 2-arm study to investigate the efficacy, safety, and tolerability of subcutaneous lunsekimig (SAR443765) in adult participants with high-risk asthma who are not currently eligible for biologic treatment. New Drug Phase Ⅱ
N202503121 A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS) New Drug Phase Ⅲ
N202504015 A Phase I Open-Label Study to Assess the Safety and Tolerability of Allogenic Human Umbilical Mesenchymal Stem Cell Therapy for Patients with Idiopathic Parkinson's Disease New Drug Phase Ⅰ
N202504046 A preliminary bioequivalence study to compare two ropinirole HCl PR tablets in healthy subjects under fed state. Bioavailability / Bioequivalence (BA/BE) NA
N202504048 A handheld fluorescence-imaging stick for detecting dental plague in patients with periodontitis New Medical Device NA
1 2 23 24 25 26 27 28 29 51 52 / 52

TOP